DOCSLIB.ORG

Fluoxetine (Prozac®)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fluoxetine (Prozac®) What is most important to remember? If you have questions: Strong Internal Medicine • It may take a few weeks for you to see the benefits of taking this Ask your doctor, nurse or pharmacist for medicine more information about fluoxetine (Prozac®). • Do not suddenly stop taking fluoxetine unless directed to do so by your doctor • Seek help from a doctor or pharmacist if you have thoughts of suicide or hurting yourself • Contact your prescriber immediately If you experience any itching or rash, or swelling of the face, lips, tongue or throat Strong Internal Medicine • Do not start any new medications, 601 Elmwood Avenue Ambulatory Care Facility, 5th Floor over-the-counter drugs or herbal Rochester, NY 14642 remedies without talking to your Phone: (585) 275 -7424 doctor Fluoxetine (Prozac®): Visit our website at: Important Patient Information • If you think there has been an www.urmc.rochester.edu/medicine/ - overdose, call your poison control general-medicine/patientcare/ center or get medical care right away What does fluoxetine (Prozac®) do? What side effects could occur with fluoxetine What are some things that I need to be aware of when • It is in a class of medications called selective serotonin (Prozac®)? taking fluoxetine (Prozac®)? reuptake inhibitors (SSRIs). It works by increasing the • Nervous and excitable, not able to sleep • Tell your doctor or pharmacist if you are allergic to fluoxetine, any other medicines, foods, or substances amount of serotonin, a natural substance in the brain • Headache that helps maintain mental balance • It may take a few weeks for you to see the benefits of • Upset stomach, diarrhea (loose stools), not hungry, dry • It is used to treat low mood (depression); anxiety; panic mouth taking this medicine. Do not suddenly stop taking attacks; obsessive-compulsive problems; post- fluoxetine unless directed to do so by your doctor • Feeling lightheaded, sleepy, or dizzy traumatic stress; and mood problems caused by • Do not take fluoxetine if you have taken other drugs for monthly periods • Change in sex ability or interest in sex depression such as MAOIs (phenelzine, tranyl- How should fluoxetine (Prozac®) be used? What should I do if I forget to take fluoxetine cypromine) or drugs for Parkinson’s disease (selegiline or (Prozac®)? rasagiline) in the last 14 days. Taking those drugs with • Use this medicine as directed by your doctor fluoxetine can cause dangerous high blood pressure. If • Take your dose as soon as you think about it • To gain the most benefit do not miss doses you are not sure, ask your doctor or pharmacist • If it is close to the time for your next dose, skip the • This medicine may be taken with or without food. If it missed dose and go back to your normal dose time • Call your doctor right away if you have dizziness, very causes upset stomach, take with food bad headache, agitation, hallucinations, fever, fast • Do not take 2 doses at the same time or extra doses Who should know I am taking fluoxetine (Prozac®)? heartbeat, a heartbeat that does not feel normal, flushing, Are there any interactions with other drugs that I need • Keep a list of all your medicines (prescription, natural seizures, shakiness, sweating a lot, change in balance, to worry about? change in thinking clearly with logic, very bad upset products, supplements, vitamins, over-the-counter) and give it to your healthcare provider (doctor, nurse, nurse • There are many drug interactions that may increase stomach and throwing up, or very bad loose stools. practitioner, pharmacist, or physician assistant) your risk of side effects These are signs of a rare but serious problem called serotonin syndrome. The risk may be greater if you take Do not start new prescription, over-the-counter fluoxetine with certain other medicines. Talk with your medicines, or herbal and dietary supplements doctor or pharmacist • Tell your doctor if you are pregnant, plan to get pregnant, or are breastfeeding. You will need to talk about the If you have any of the following side effects, call your doctor or visit the emergency room benefits and risks of using this medication immediately: • This medicine may raise your chance of bleeding. Talk • If you are planning to hurt yourself • Trouble breathing with your doctor if you are taking aspirin or blood thinners • Change in thinking clearly • Itching or rash • Fluoxetine may make you drowsy. Do not drive a car or • Very bad dizziness or passing out • Swelling of face, lips, tongue or throat operate machinery until you know how this medicine affects you • Very upset stomach or throwing up • Twitching, agitation, sweating a lot, • Avoid drinking alcohol (includes wine, beer, and liquor) • Very loose stools and muscle stiffness • If you are 65 or older, use this medicine with care. You • Any bruising or bleeding • Very excitable and nervous may have more side effects • Big change in balance • A heartbeat that does not feel normal • Store a cool, dry place. Keep out of reach of children and • pets .
Load more

Recommended publications
  • Isoflurane Produces Antidepressant Effects and Induces Trkb Signaling in Rodents
    bioRxiv preprint doi: https://doi.org/10.1101/084525; this version posted July 11, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Isoflurane produces antidepressant effects and induces TrkB signaling in rodents Hanna Antilaa, Maria Ryazantsevaa,b, Dina Popovaa, Pia Sipiläa, Ramon Guiradoa, Samuel Kohtalaa,b, Ipek Yalcinc, Jesse Lindholma, Liisa Vesaa, Vinicius Satod, Joshua Cordeirae, Henri Autioa, Mikhail Kislina, Maribel Riose, Sâmia Jocad, Plinio Casarottoa, Leonard Khirouga, Sari Lauria,b, Tomi Tairaa,f, Eero Castréna* and Tomi Rantamäkia,b* aNeuroscience Center, P.O. Box 56, FI-00014 University of Helsinki, Helsinki, Finland. bDivision of Physiology and Neuroscience, Department of Biosciences, Faculty of Biological and Environmental Sciences, P.O. Box 66, FI-00014 University of Helsinki, Helsinki, Finland. cInstitut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, FR-67084 Strasbourg Cedex, France. dSchool of Pharmaceutical Sciences of Ribeirão Preto 14040-903, Brazil. eTufts University, Boston, MA, USA. fDepartment of Veterinary Biosciences, Faculty of Veterinary Medicine P.O. Box 66, FI-00014 University of Helsinki, Helsinki, Finland. *To whom correspondence should be addressed at: Eero Castrén ([email protected]) or Tomi Rantamäki ([email protected]) A brief burst-suppressing isoflurane anesthesia has been shown to rapidly alleviate symptoms of depression in a subset of patients, but the neurobiological basis of these observations remains obscure. We show that a single isoflurane anesthesia produces antidepressant-like behavioural effects in the learned helplessness paradigm and regulates molecular events implicated in the mechanism of action of rapid-acting antidepressant ketamine: activation of brain-derived neurotrophic factor (BDNF) receptor TrkB, facilitation of mammalian target of rapamycin (mTOR) signaling pathway and inhibition of glycogen synthase kinase 3β (GSK3β).
    [Show full text]
  • Effects of in Vitro Amitriptyline, Fluoxetine, Tranylcypromine and Venlafaxine on Saphenous Vein Grafts
    ORIGINAL ARTICLE Braz J Cardiovasc Surg 2019;34(3):290-6 Effects of in vitro Amitriptyline, Fluoxetine, Tranylcypromine and Venlafaxine on Saphenous Vein Grafts Melek Akinci1, MD; Cetin Hakan Karadag2, MD; Serhat Huseyin3, MD; Cagatay Oltulu4, MD; Suat Canbaz3, MD; Ozgur Gunduz2, MD; Ruhan Deniz Topuz2, MD DOI: 10.21470/1678-9741-2018-0338 Abstract Objective: In this study, we aimed to examine the effects of (Log M) was 74.6%, the response at -6.32 (Log M) was 75.5%. amitriptyline, fluoxetine, tranylcypromine and venlafaxine on While the relaxation response at -6.46 (Log M) of fluoxetine was saphenous vein grafts in coronary artery bypass graft surgeries. 68.02%, the response at -6.02 (Log M) was 72.12%. While the Methods: 59 patients (40 males and 19 females; mean age relaxation response of tranylcypromine at -7.53 (Log M) was 65.1 years, distribution: 45-84 years) who had coronary artery 61.13%, the response at -7.23 (Log M) was 65.53%. While the bypass graft surgery between February 2014 and May 2016 were relaxation response of venlafaxine at -6.21 (Log M) was 29.98%, included in the study. After the saphenous vein grafts with intact the response at -5.90 (Log M) was 32.96%. and denuded endothelium were precontracted with 3×10-6M Conclusion: The maximum relaxation at minimum and phenylephrine, amitriptyline, fluoxetine and tranylcypromine maximum therapeutic concentrations was obtained with were cumulatively added to isolated organ baths in the range of amitriptyline, fluoxetine and tranylcypromine, and the minimum 10-11-3x10-5M, while venlafaxine was added in the range of 10-9- relaxation was obtained with venlafaxine.
    [Show full text]
  • Psychotropic Drugs: Sedatives/Hypnotics, Antidepressants, and Antipsychotics
    PSYCHOTROPIC DRUGS: SEDATIVES/HYPNOTICS, ANTIDEPRESSANTS, AND ANTIPSYCHOTICS INSTIs NNRTIs PIs RTI xBICTEGRAVIR xELVITEGRAVIR/ x DORAVIRINE x EFAVIRENZ xATAZANAVIR • TENOFOVIR • TENOFOVIR (Biktarvy) COBICISTAT (Pifeltro, (Sustiva, Atripla) (Reyataz/Norvir, ALAFENAMIDE, DISOPROXIL, TDF (Stribild, Genvoya) Delstrigo) Evotaz) TAF (Descovy, (Viread,Truvada, DOLUTEGRAVIR ETRAVIRINE x x Biktarvy, Genvoya, Atripla, Complera, (Tivicay, Triumeq, RILPIVIRINE (Intelence) DARUNAVIR x x Odefsey, Symtuza) Delstrigo, Stribild) Juluca) (Edurant, (Prezista/Norvir, x NEVIRAPINE Complera, Prezcobix, x RALTEGRAVIR (Viramune) •ABACAVIR (Kivexa, Odefsey, Juluca) Symtuza) (Isentress) Ziagen, Triumeq) xLOPINAVIR (Kaletra) SEDATIVES/HYPNOTICS xLorazepam, oxazepam, temazepam xAlprazolam, Potential for n Potential for p Potential for n bromazepam, benzodiazepine benzodiazepine benzodiazepine buspirone, clonazepam, estazolam, flurazepam, diazepam, nitrazepam, zolpidem, zopiclone xMidazolam, Potential for n Potential for p Potential for n triazolam benzodiazepine benzodiazepine benzodiazepine PSYCHOTROPICS INSTIs NNRTIs PIs RTI xBICTEGRAVIR xELVITEGRAVIR/ x DORAVIRINE x EFAVIRENZ xATAZANAVIR • TENOFOVIR • TENOFOVIR (Biktarvy) COBICISTAT (Pifeltro, (Sustiva, Atripla) (Reyataz/Norvir, ALAFENAMIDE, DISOPROXIL, TDF (Stribild, Genvoya) Delstrigo) Evotaz) TAF (Descovy, (Viread,Truvada, DOLUTEGRAVIR ETRAVIRINE x x Biktarvy, Genvoya, Atripla, Complera, (Tivicay, Triumeq, RILPIVIRINE (Intelence) DARUNAVIR x x Odefsey, Symtuza) Delstrigo, Stribild) Juluca) (Edurant, (Prezista/Norvir,
    [Show full text]
  • Supplementary Material Exploring the Efficiency of UHPLC-Orbitrap MS For
    Supplementary Material Exploring the efficiency of UHPLC-Orbitrap MS for the determination of 20 pharmaceuticals and acesulfame K in hospital and urban wastewaters with the aid of FPSE Maria Kalaboka, Christoforos Chrimatopoulos, Cristina Jiménez-Holgado, Vasiliki Boti, Vasilios Sakkas, * and Triantafyllos Albanis University of Ioannina, Chemistry Department, 45110 Ioannina, Greece; [email protected], [email protected] , [email protected], [email protected], talbanis@uoi,gr, [email protected] * Correspondence: [email protected]; Tel.: +30-2651008303 Table S1: Physicochemical properties and chemical structures of target analytes Molecular Therapeutic Compound Chemical Structure pKa [Ref.] logP Formula class - Artificial Acesulfame C4H5NO4S 2.0 [1] 0.552 Sweetener tricyclic Amitriptiline C20H23N 9.4 [2] 4.81 antidepressant s Psychiatric Carbamazepine C15H12N2O 7.0/13.9 [3] 2.766 Antiepileptic Drugs Psychiatric Clomipramine C19H23ClN2 8.98 [4] 4.883 Antidepressant Drugs Psychiatric Cyclobenzaprine C20H21N 8.47 [5] 4.613 Antidepressant Drugs Non-steroidal anti- Diclofenac C14H11Cl2NO2 4.2 [3] 4.259 inflammatory drug (NSAID) Macrolide Erythromycin C37H66NO12 8.9 [3] 2.596 Antibiotic Antidepressant Fluoxetine C17H18F3NO 10.1 [6] 4.173 Drugs Analgesic-anti- Indomethacin C19H16ClNO4 4.27 [3] 3.53 inflammatory drug Nonsteroidal anti- Mefenamic Acid C15H15NO2 4.2 [7] 5.398 inflammatory drugs (NSAID) Psychiatric Paroxetine C19H20O3NF 9.6 [6] 3.148 Antidepressant Drugs Non-steroidal anti- Salicylic acid C7H6O3 2.3/3.5 [6] 1.977 inflammatory drug (NSAID) Sulfonamide Sulfacetamide C8H10N2O3S 5.4 [8] -0.3 Antibiotic Sulfonamide Sulfamethazine C12H14N4O2S 7.6/2.65 [9] 0.65 Antibiotic Sulfonamide Sulfamethoxazole C10H11N3O3S 5.7/1.6 [9] 0.791 Antibiotic Sulfamethoxy- Sulfonamide C11H12N4O3S 6.7 [9] 0.466 pyridazine Antibiotic 6.24/2.
    [Show full text]
  • Disproportionality Analysis of Antiretrovirals
    Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, March 3–6 2014 Poster #761 Disproportionality Analysis of Antiretrovirals with Suicidality using FDA Adverse Event Reporting System (FAERS) Data Daniel Seekins Andrew Napoli1, John Coumbis2, Jennifer Wood2, Amit Soitkar2, Daniel Seekins1 Bristol-Myers Squibb, Plainsboro, NJ, USA 1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2Bristol-Myers Squibb, Hopewell, NJ, USA Email: [email protected] INTRODUCTION Statistical Analysis Suicide Attempt CONSIDERATIONS n A disproportionality analysis was performed for the selected drug and selected AE using the MGPS method Efavirenz (n = 107) Antiretrovirals n Psychiatric events, including depression, suicidal ideation, suicide attempts, and completed Antidepressants Strengths suicide have been reported in patients receiving efavirenz since 19981 Etravirine (n = 4) n The disproportionality measure, Empirical Bayesian Geometric Mean (EBGM), and the EB05 n FAERS is a large, independent, public dataset containing real-world data that can enable corresponding 90% CI (EB05, EB95) were estimated Nevirapine (n = 41) EBGM n Recently, a pooled analysis of four AIDS Clinical Trials Group (ACTG) studies (A5095, A5142, EB95 identification of potential signals for rare AEs A5175, A5202), identified an increased rate of suicidality with efavirenz-containing regimens n The threshold score above which a drug-event disproportionality signal is likely to be present Atazanavir (n = 13) compared to efavirenz-free regimens: is an EB05
    [Show full text]
  • Pharmacokinetics and Pharmacology of Drugs Used in Children
    Drug and Fluid Th erapy SECTION II Pharmacokinetics and Pharmacology of Drugs Used CHAPTER 6 in Children Charles J. Coté, Jerrold Lerman, Robert M. Ward, Ralph A. Lugo, and Nishan Goudsouzian Drug Distribution Propofol Protein Binding Ketamine Body Composition Etomidate Metabolism and Excretion Muscle Relaxants Hepatic Blood Flow Succinylcholine Renal Excretion Intermediate-Acting Nondepolarizing Relaxants Pharmacokinetic Principles and Calculations Atracurium First-Order Kinetics Cisatracurium Half-Life Vecuronium First-Order Single-Compartment Kinetics Rocuronium First-Order Multiple-Compartment Kinetics Clinical Implications When Using Short- and Zero-Order Kinetics Intermediate-Acting Relaxants Apparent Volume of Distribution Long-Acting Nondepolarizing Relaxants Repetitive Dosing and Drug Accumulation Pancuronium Steady State Antagonism of Muscle Relaxants Loading Dose General Principles Central Nervous System Effects Suggamadex The Drug Approval Process, the Package Insert, and Relaxants in Special Situations Drug Labeling Opioids Inhalation Anesthetic Agents Morphine Physicochemical Properties Meperidine Pharmacokinetics of Inhaled Anesthetics Hydromorphone Pharmacodynamics of Inhaled Anesthetics Oxycodone Clinical Effects Methadone Nitrous Oxide Fentanyl Environmental Impact Alfentanil Oxygen Sufentanil Intravenous Anesthetic Agents Remifentanil Barbiturates Butorphanol and Nalbuphine 89 A Practice of Anesthesia for Infants and Children Codeine Antiemetics Tramadol Metoclopramide Nonsteroidal Anti-infl ammatory Agents 5-Hydroxytryptamine
    [Show full text]
  • Antidepressant Drugs in Oral Fluid Using Liquid Chromatography –Tandem Mass Spectrometry
    Journal of Analytical Toxicology, Vol. 34, March 2010 Antidepressant Drugs in Oral Fluid Using Liquid Chromatography –Tandem Mass Spectrometry Cynthia Coulter, Margaux Taruc, James Tuyay, and Christine Moore* Immunalysis Corporation, 829 Towne Center Drive, Pomona, California 91767 Abstract graines, or sleep disorders. Antidepressant drugs may also cause impairment of cognitive and psychomotor functioning An analytical procedure for the determination of widely relevant to driving, although this impairment is reportedly prescribed drugs for the treatment of depression and anxiety less severe in second generation antidepressants such as se - disorders, including amitriptyline, cyclobenzaprine, imipramine, lective serotonin reuptake inhibitors (SSRIs) than with more dothiepin, doxepin, fluoxetine, sertraline, trimipramine, traditional tricyclic antidepressants (TCAs) such as amitripty - protriptyline, chlorpromazine, clomipramine, and some of their line (1,2). Patients receiving long-term treatment with SSRI metabolites (nortriptyline, desmethyldoxepin, desipramine, and serotonin-norepinephrine reuptake inhibitor (SNRI)-type desmethyltrimipramine, norclomipramine) in oral fluid has been drugs produce impaired driving performance (3). However, developed and validated using liquid chromatography with tandem Brunnauer et al. (2) showed that there were actually no sta - mass spectral detection. The oral fluid samples were collected using the Quantisal™ device, screened with enzyme-linked tistically significant differences between patients treated
    [Show full text]
  • Neurological Diseases of Children
    Anesthetic Issues in Children with Neurologic Diseases Robert S. Rust, MA, MD Thomas E. Worrell Professor of Epileptology and Neurology Professor of Pediatrics Director of Child Neurology University of Virginia Nothing to Declare Generalities • Common pro blems in c hildren w ith var ious neurologic diseases: • Cortical issues (intelligence, behavior, etc.) • Visual or hearing disturbances • Oropharyngeal, pulmonary mechanical problems • Cervical instability or torticollis • RflReflux • Contractures, weakness/hypotonia • Movement disorders • Seizures and antiseizure medications Intubation-related risks Approach to individuals with epilepsy • Avoid prolonged preoperative fast • 18+ ASDs —avoid holding doses pre/post • Depends on half-time drug elimination • Oral with small sip/rectal/IV • Anesthetic choice/dose: consider ASD etc. med • Care w ith hyperven tila tion /hypocar bia • Reduction of CBF v worsening metab/EEG • Care in interpretation of cause or nature of twitching, tonicity, shivering, confusion Anesthetics with effects on seizure threshold (sometimes…) • Enflurane Proconvulsant • Etomidate Proconvulsant • Sevoflurane Proconvulsant • FtFentanyl Pro- or anticonvu lsan t • Ketamine Pro- or anticonvulsant* • Lidocaine Pro- or anticonvulsant • Methohexital Proconvulsant • Morphine Pro- or anticonvulsant •Propofol Pro- or anticonvulsant* • Etc. * Particularlyyg useful treating BDZ-resistant status epppilepticus Receptor trafficking Inhalational Anesthetics (1) • Enflurane: proconvulsant • Organic/inorganic flourinated metabolites • No Epilepsy: Facial/appendicular myoclonus – No associated convulsive EEG abnormalities – Deep levels have been associated with GTC szs • Epilepsy: concn-related worsening szs + EEG abn – HV (to decrease CFB/ICP) worsens enflurane effect – DZP, thiopental may worsen enflurane effects – Nitrous not known to have + or – influence – Post-op GTC/myoclonic szs may persist for days Inhalational Anesthetics (2) • IflIsoflurane – Little proconvulsive--except co-admin of nitrous?) – Valuable anticonvulsant effects (esp.
    [Show full text]
  • Medicinal Herbs with Anti-Depressant Effects
    J Herbmed Pharmacol. 2020; 9(4): 309-317. http://www.herbmedpharmacol.com doi: 10.34172/jhp.2020.39 Journal of Herbmed Pharmacology Medicinal herbs with anti-depressant effects Mahbubeh Setorki* ID Department of Biology, Izeh Branch, Islamic Azad University, Izeh, Iran A R T I C L E I N F O A B S T R A C T Article Type: Depression is a life-threatening chronic illness which affects people worldwide. Drugs used to Review treat this disease have multiple side effects and may cause drug-drug or drug-food interactions. Additionally, only 30% of patients respond adequately to the existing drugs and the remaining Article History: do not achieve complete recovery. Thus, finding effective treatments that have adequate Received: 10 November 2018 efficacy, fewer side effects and lower cost seem to be necessary. The purpose of this study was Accepted: 24 January 2019 to review animal and double-blind clinical studies on the anti-depressant effects of medicinal herbs. In this study, validated scientific articles indexed in PubMed, SID, Web of Science and Keywords: Scopus databases were reviewed. A database search was performed using the following terms: Depression clinical trials, depression, major depressive disorder, essential oil, extract and medicinal plant. Clinical trials Positive effects of a number of herbs and their active compounds such as St John’s-wort, saffron, Medicinal plants turmeric, ginkgo, chamomile, valerian, Lavender, Echium amoenum and Rhodiola rosea L. in Herbal medicines improvement of symptoms of mild, moderate or major depression have been shown in clinical trials. The above plants show antidepressant effects and have fewer side effects than synthetic drugs.
    [Show full text]
  • Understanding Drug Interactions in Dental Practice
    2019 Understanding Drug Interactions in Dental Practice Money Makes the World Go Round, But Drugs Can Make it Spin! Dr. Mark Donaldson, BSP, RPH, ACPR, PHARMD, FASHP, FACHE Associate Vice President Vizient Pharmacy Advisory Solutions [email protected] Our Clinician: Dr. Mark Donaldson BSP, RPH, PHARMD, FASHP, FACHE received his baccalaureate degree from the University of British Columbia and his Doctorate in Clinical Pharmacy from the University of Washington. He completed a residency at Vancouver General Hospital, and has practiced as a clinical pharmacy specialist, clinical coordinator and director of pharmacy services at many healthcare organizations in both Canada and the United States. He is currently the Associate Vice President of Clinical Pharmacy for Vizient’s Advisory Solutions, and lives in Whitefish, Montana. Dr. Donaldson is a Clinical Professor in the Department of Pharmacy at the University of Montana in Missoula, Clinical Associate Professor in the School of Dentistry at the Oregon Health & Sciences University in Portland, Oregon, and affiliate faculty in the School of Dentistry at UBC. He has a special interest in dental pharmacology and has lectured internationally to both dental and medical practitioners. He has spent the last 20 years focusing on dental pharmacology and dental therapeutics, and is a leader in the field. Dr. Donaldson has published numerous peer-reviewed works and textbook chapters. He currently serves on the Editorial Board for the Journal Healthcare Executive and the Journal of the American Dental Association and is a reviewer for over ten other different journals. He is board certified in healthcare management and is the Past- President and current Regent of the American College of Healthcare Executives’ Montana Chapter.
    [Show full text]
  • Using Fluoxetine As a Model
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by OAR@UM Review Journal of Pharmacy And Pharmacology Understanding the molecular pharmacology of the serotonergic system: using fluoxetine as a model Lino Sghendo and Janet Mifsud Department of Clinical Pharmacology and Therapeutics, University of Malta, Msida, Malta Keywords Abstract molecular and clinical pharmacology; molecular and receptor pharmacology; Objectives Serotonin is a monoamine neurotransmitter that is widely distributed pharmacokinetics and drug disposition in the body and plays an important role in a variety of psychological and other body functions such as mood, sexual desire and function, appetite, sleep, memory and Correspondence learning, temperature regulation and social behaviour. This review will assess the Janet Mifsud, Department of Clinical use of fluoxetine, one of the most commonly used selective serotonin reuptake Pharmacology and Therapeutics, University of Malta, Msida, MDS2040, Malta. inhibitors, as a model for understanding the molecular pharmacology of the sero- E-mail: [email protected] toninergic system. Key findings Seven serotonin receptor families have been discovered to date. All Received June 21, 2011 serotonin receptors, except 5-HT3, are G-protein coupled, seven transmembrane Accepted September 22, 2011 receptors that activate an intracellular second messenger cascade. The 5-HT3 recep- tor is a ligand-gated ion channel. Furthermore, 5-HT1A receptors are known as doi: 10.1111/j.2042-7158.2011.01384.x autoreceptors since their stimulation inhibits the release serotonin in nerve termi- nals.A transporter protein found in the plasma membrane of serotonergic neurones is responsible for the reuptake of this neurotransmitter.
    [Show full text]
  • Antidepressant Medications: U.S. Food and Drug Administration
    Antidepressant Medications: U.S. Food and Drug Administration-Approved Indications and Dosages for Use in Adults The therapeutic dosing recommendations for antidepressant medications are based on U.S. Food and Drug Administration (FDA)-approved product labeling. Nevertheless, the dosing regimen is adjusted according to a patient’s individual response to pharmacotherapy. The FDA-approved indications and dosages for the use of antidepressant medications in adults are provided in this table. Some of the antidepressant medications are FDA-approved for the treatment of or as adjunct therapy for Parkinson’s disease. This indication is not discussed in this document because of its very specific focus and individualized treatment regimens. All of the antidepressant medications listed are for oral administration unless otherwise stated. Information on the generic availability of antidepressant medications can be found by searching the Electronic Orange Book at https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm on the FDA website. Generic Medication Indication Initial Dose Maximum Dose Other Information Availability amitriptyline[1] depression Outpatients: Outpatients: Outpatients may be initiated at 50 mg Yes 75 mg per day; 150 mg per day; to 100 mg once a day at bedtime. Dose Hospitalized patients: Hospitalized patients: increases should be made gradually by 100 mg per day 300 mg per day 25 mg to 50 mg as necessary, preferably in the late afternoon or evening. Lower doses are recommended for elderly patients. Take in divided doses. amoxapine[2] depression 50 mg 2 or 3 times a day 400 mg per day; May increase dose to 100 mg 2 to 3 times Yes Hospitalized patients a day by the end of the first week.
    [Show full text]